Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Moolec Science SA Ordinary Shares (MLEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MLEC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.53% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.78M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.32 | 52 Weeks Range 2.31 - 10.47 | Updated Date 08/15/2025 |
52 Weeks Range 2.31 - 10.47 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.69% | Return on Equity (TTM) -174.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 29936767 | Price to Sales(TTM) 1.2 |
Enterprise Value 29936767 | Price to Sales(TTM) 1.2 | ||
Enterprise Value to Revenue 3.82 | Enterprise Value to EBITDA -1.01 | Shares Outstanding 4000370 | Shares Floating 897815 |
Shares Outstanding 4000370 | Shares Floating 897815 | ||
Percent Insiders 27.12 | Percent Institutions 0.1 |
Upturn AI SWOT
Moolec Science SA Ordinary Shares
Company Overview
History and Background
Moolec Science SA is a food technology company focused on producing animal proteins in plants through molecular farming. Founded in 2020, it aims to provide sustainable and scalable solutions for the alternative protein market.
Core Business Areas
- Molecular Farming: Moolec genetically modifies plants to produce animal proteins, aiming to create ingredients for the food industry in a more sustainable manner.
- Ingredient Development: The company focuses on developing and commercializing these plant-based ingredients for use in various food products.
Leadership and Structure
Gastu00f3n Paladini is the CEO. The company operates with a research and development team focused on gene editing and protein production in plants.
Top Products and Market Share
Key Offerings
- Soybean-produced Bovine Myoglobin (Piggy Sooy): This product aims to produce bovine myoglobin, a key protein in beef, using soybeans. Initial commercialization is the focus. Competitors: Impossible Foods (plant-based heme), Motif FoodWorks (heme analogs).
- Pea-produced Porcine Protein: This project focuses on producing porcine collagen and other pig proteins in peas for use in food applications. Competitors: Gelita, Rousselot (traditional collagen production).
Market Dynamics
Industry Overview
The alternative protein market is growing rapidly, driven by concerns about sustainability and animal welfare. Molecular farming is an emerging technology within this space.
Positioning
Moolec aims to differentiate itself by producing animal proteins directly in plants, potentially offering a more cost-effective and scalable solution compared to cell-based meat and traditional animal agriculture.
Total Addressable Market (TAM)
The total addressable market for alternative proteins is projected to reach hundreds of billions of dollars within the next decade. Moolec is positioned to capture a share of this market with its molecular farming technology, focusing on specialty ingredients for food companies.
Upturn SWOT Analysis
Strengths
- Innovative technology (molecular farming)
- Potential for scalable and sustainable production
- Focus on high-value animal proteins
Weaknesses
- Early stage of development
- Regulatory hurdles for genetically modified crops
- Public perception of GMOs
Opportunities
- Growing demand for alternative proteins
- Partnerships with food companies
- Advancements in gene editing technology
Threats
- Competition from other alternative protein companies
- Regulatory changes
- Consumer resistance to GMOs
- Challenges in scaling up production
Competitors and Market Share
Key Competitors
- IMCR.MI
- BYND
- TSN
Competitive Landscape
Moolec's competitive advantage lies in its molecular farming approach, potentially offering cost advantages over cell-based meat and plant based alternatives. However, it faces competition from established players with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as the company is in the early stages.
Future Projections: Future growth is dependent on successful product development, regulatory approvals, and market adoption. Analyst estimates are not widely available but depend on successful commercialization of their technology.
Recent Initiatives: Focusing on scaling up production of Piggy Sooy, securing regulatory approvals, and partnering with food companies.
Summary
Moolec Science SA is an early-stage company pioneering molecular farming to produce animal proteins in plants. This innovative approach has the potential to offer sustainable and scalable solutions for the alternative protein market but faces regulatory hurdles, public perception issues, and competition from established players. Successful execution of its strategy depends on scaling production, securing partnerships, and obtaining regulatory approvals. Given current market conditions it is a risk/reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The alternative protein market is rapidly evolving, and the information presented here may not be current.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moolec Science SA Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-01-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://moolecscience.com |
Full time employees - | Website https://moolecscience.com | ||
Moolec Science SA operates as a science-based food ingredient company, focuses on developing ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology. The company is based in Grand Cayman, Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.